RetinaCME
EXPERT VIDEOCMEABO MOC

Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Options for Sustained Delivery

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Dante J. Pieramici, MD; Charles C. Wykoff, MD, PhD
Release Date: 4/30/2021Expiration Date: 4/29/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: VideoProvider:
Treatment burden and subsequent loss of patient adherence are significant factors associated with less-than-optimal visual acuity gains seen in real-world outcomes in patients with neovascular retinal diseases. Ongoing clinical studies are evaluating novel delivery systems, gene therapies, and agents that enhance dosing intervals while targeting novel pathways with the potential to reduce treatment burden and improve visual acuity outcomes. In this educational activity, Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases – Session on Options for Sustained Delivery, experts in the field evaluate the evidence demonstrated in clinical trials regarding treatment protocols and their application to real-world practice as well as examine emerging delivery systems and gene therapies that allow for extended intervals between treatments for neovascular retinal diseases.